The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche's Rituxan.
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Judy Smythe, Bardia Akbari and Niv Caviar have been named as the company's chief operating officer, senior vice president of clinical operations and chief financial officer, respectively.
Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.
Moving right along... Roche quietly disclosed in its Q1 financial report that it has scrapped a Phase 2 breast cancer asset, acquired in a $725 million buyout of Seragon Pharmaceuticals.
It seems there's no longer any tolerance for the 'how far can we push this' approach. The smart players are instead asking 'what is reasonable and sustainable in our current healthcare climate?'
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Late Tuesday, the 20-year-old Rituxan dynasty gave birth to a new multiple sclerosis drug, Ocrevus.
Genentech, whose drug Avastin is approved to treat advanced cervical cancer, has launched a contest offering $50K to startups with innovative approaches to address the disease.
Although nearly 250 companies are working in the breast cancer treatment space, growth in the market will be driven by the uptake of three new drugs over the next 10 years and will plateau by 2018, according to a new market analysis from Decision Resources. Those three drugs will be Genentech’s Perjeta, which was approved […]
Current medical news from today, including former Genentech CEO Art Levinson appointed chairman of Apple, Johnson & Johnson to remove toxins from baby products, and Pfizer gets panel support for Prevnar in older adults.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. Now here's the best of what YOU had to say.
Cleveland Clinic neuromodulation spinoff Intelect Medical may have stealthily exited Cleveland to set up shop in Boston, but the company's recent $78 million sale to Boston Scientific (NYSE: BSX) highlights Northeast Ohio's growing strength in neurotechnology. Here's a brief overview of the key players in Northeast Ohio's rising neurotechnology industry.
Unequal access to healthcare is hardly a new phenomenon in the United States, but the country is moving toward rationing at an unprecedented pace. The underlying problem is that doctors are reimbursed at different rates, reports the New York Times.
You certainly can’t accuse Bruce Barclay of standing still. Since SurModics Inc. (NASDAQ: SRDX) named Barclay CEO in 2005, Barclay has reorganized the drug company’s business units, purchased land, signed licensing agreements, acquired several companies and expanded into ophthalmology and drug development. Yet the company, based in Eden Prairie, Minn., still has little to show […]
Attention Minnesota: the Food and Drug Administration wants your orphans. In August, the University of Minnesota will host a FDA workshop where the agency will help area researchers, biotech firms and drug companies apply for “orphan drug” status, a fast-track approval program for drugs that treat rare diseases like Huntington’s disease, myoclonus, ALS (Lou Gehrig’s […]